Wire · regulatory
U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 September 2026 · Fusion42 review
The U.S. FDA has approved the combination of WELIREG® (belzutifan) and LENVIMA® (lenvatinib) for treating certain previously treated adult patients with advanced renal cell carcinoma with a clear cell component. This approval is based on Phase 3 trial results demonstrating the combination's efficacy following PD-1/PD-L1 inhibitor treatment failure.
This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 24 Sep 2026 and 28 Sep 2026.
◆ ◆ The Wire takeaway
You gain access to a new regulatory precedent easing market entry for combination therapies in renal cancer. This loosens barriers to launch multi-drug regimens targeting treatment-resistant patients.
◆ Coverage
8 sources · first reported 24 Sep 2026 · latest 28 Sep 2026
◆ Related on Wire
◆ Topics